← back to search

Peter J. Parker

King's College London · GB
Area of research
Molecular Biology · Cell Biology
Research interest
Research interests include Protein Kinase Regulation and GTPase Signaling, Cellular transport and secretion, PI3K/AKT/mTOR signaling in cancer, and Receptor Mechanisms and Signaling.
h-index
105
citations
42,299
works
635
NIH funding
primary concept
Chemistry
email

Recent publications

Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function.
2025cited by 0position: contributordoi
Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers
Nature Communications 2024cited by 47position: middledoi
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer
Journal of Clinical Oncology 2023cited by 77position: middledoi
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
2023cited by 45position: contributordoi
Cell cycle responses to Topoisomerase II inhibition: Molecular mechanisms and clinical implications.
2023cited by 14position: contributordoi
Chemical Genetic Identification of PKC Epsilon Substrates in Mouse Brain
Molecular & Cellular Proteomics 2023cited by 3position: middledoi
The T766M-EGFR lung cancer mutation promotes tumor growth by exploiting newfound mechanisms assembling ligand-free EGFR oligomer structures
2023cited by 0position: contributordoi
Control of atypical PKCι membrane dissociation by tyrosine phosphorylation within a PB1-C1 interdomain interface
2023cited by 0position: contributordoi
Into the fold: advances in understanding aPKC membrane dynamics.
2023cited by 0position: contributordoi
Michael D. Waterfield
Biochemical Journal 2023cited by 0position: contributordoi
The <i>Candida albicans</i> toxin candidalysin mediates distinct epithelial inflammatory responses through p38 and EGFR-ERK pathways.
2022cited by 52position: contributordoi
Editorial: Signaling by Small GTPases in Metastatic Disease.
2022cited by 1position: contributordoi
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
2021cited by 217position: contributordoi
Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts
Gastroenterology 2021cited by 139position: middledoi
Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
2021cited by 109position: contributordoi
Equivocal, explicit and emergent actions of PKC isoforms in cancer.
2021cited by 52position: contributordoi
A genetically-encoded crosslinker screen identifies SERBP1 as a PKCε substrate influencing translation and cell division.
2021cited by 21position: contributordoi
<i>ImmunoCluster</i> provides a computational framework for the nonspecialist to profile high-dimensional cytometry data.
2021cited by 17position: contributordoi
Co-ordinated control of the Aurora B abscission checkpoint by PKCε complex assembly, midbody recruitment and retention.
2021cited by 9position: contributordoi
Quantification of biomarker functionality predicts patient outcomes.
2021cited by 5position: contributordoi
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Cell Reports 2020cited by 75position: middledoi
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Nature reviews. Cancer 2020cited by 62position: firstdoi
High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
Cancer Research 2020cited by 45position: middledoi
The Aurora B specificity switch is required to protect from non-disjunction at the metaphase/anaphase transition.
2020cited by 12position: contributordoi
A small molecule inhibitor of HER3: a proof-of-concept study.
2020cited by 9position: contributordoi
A cancer-associated, genome protective programme engaging PKCε.
2020cited by 7position: contributordoi
Immunogenomic profile of colorectal cancer response to immune checkpoint blockade
2020cited by 2position: contributordoi
Immune-checkpoint engagement as predictive biomarkers in clear cell renal cell carcinoma and melanoma
2020cited by 0position: contributordoi
A genome-wide RNAi screen identifies the SMC5/6 complex as a non-redundant regulator of a Topo2a-dependent G2 arrest.
2019cited by 24position: contributordoi
The Rho family GEF FARP2 is activated by aPKCι to control tight junction formation and polarity.
2019cited by 14position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 9 papers (2019–2025)Mark Linch · University College Hospital6 papers (2013–2020) · 6 papers (2015–2024) · 5 papers (2016–2024)Philippe Riou · Altrincham Hospital5 papers (2013–2016) · 5 papers (2015–2024)Neil Q. McDonald · Newcastle University4 papers (2013–2020) · 4 papers (2016–2024) · 4 papers (2013–2018) · 4 papers (2013–2016)Michael Howell · Saint Francis Health System4 papers (2015–2019) · 4 papers (2016–2024)Mathias Cobbaut · The Francis Crick Institute4 papers (2019–2023)Neil Q. McDonald · The Francis Crick Institute4 papers (2021–2025)Tony Ng · King's College London3 papers (2015–2020) · 3 papers (2016–2018) · 3 papers (2016–2018) · 3 papers (2013–2016) · 3 papers (2016–2018)Paul R. Barber · King's College London3 papers (2015–2021)